JP2014529629A5 - - Google Patents

Download PDF

Info

Publication number
JP2014529629A5
JP2014529629A5 JP2014528963A JP2014528963A JP2014529629A5 JP 2014529629 A5 JP2014529629 A5 JP 2014529629A5 JP 2014528963 A JP2014528963 A JP 2014528963A JP 2014528963 A JP2014528963 A JP 2014528963A JP 2014529629 A5 JP2014529629 A5 JP 2014529629A5
Authority
JP
Japan
Prior art keywords
chem
xaa
lys
linker
derivative according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014528963A
Other languages
English (en)
Japanese (ja)
Other versions
JP6126097B2 (ja
JP2014529629A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/067364 external-priority patent/WO2013037690A1/en
Publication of JP2014529629A publication Critical patent/JP2014529629A/ja
Publication of JP2014529629A5 publication Critical patent/JP2014529629A5/ja
Application granted granted Critical
Publication of JP6126097B2 publication Critical patent/JP6126097B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014528963A 2011-09-06 2012-09-06 Glp−1誘導体 Active JP6126097B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11180265 2011-09-06
EP11180265.8 2011-09-06
US201161532323P 2011-09-08 2011-09-08
US61/532,323 2011-09-08
PCT/EP2012/067364 WO2013037690A1 (en) 2011-09-06 2012-09-06 Glp-1 derivatives

Publications (3)

Publication Number Publication Date
JP2014529629A JP2014529629A (ja) 2014-11-13
JP2014529629A5 true JP2014529629A5 (enExample) 2015-10-01
JP6126097B2 JP6126097B2 (ja) 2017-05-10

Family

ID=47882647

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014528963A Active JP6126097B2 (ja) 2011-09-06 2012-09-06 Glp−1誘導体

Country Status (6)

Country Link
US (2) US9758560B2 (enExample)
EP (1) EP2753642B8 (enExample)
JP (1) JP6126097B2 (enExample)
CN (2) CN107266558A (enExample)
ES (1) ES2626013T3 (enExample)
WO (1) WO2013037690A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6366575B2 (ja) 2012-05-08 2018-08-01 ノヴォ ノルディスク アー/エス 二重アシル化されたglp−1誘導体
WO2013167454A1 (en) 2012-05-08 2013-11-14 Novo Nordisk A/S Double-acylated glp-1 derivatives
HUE057361T2 (hu) * 2013-05-28 2022-05-28 Takeda Pharmaceuticals Co Peptid vegyület
CN106132985B (zh) * 2014-04-07 2020-10-13 诺和诺德股份有限公司 双酰化glp-1化合物
JP2018012644A (ja) * 2014-11-26 2018-01-25 武田薬品工業株式会社 ペプチド化合物
MX2018012700A (es) * 2016-04-28 2019-01-30 Novo Nordisk As Semaglutida en afecciones cardiovasculares.
WO2017204219A1 (ja) 2016-05-24 2017-11-30 武田薬品工業株式会社 ペプチド化合物
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
EP3474820B1 (en) 2017-08-24 2024-02-07 Novo Nordisk A/S Glp-1 compositions and uses thereof
PE20211417A1 (es) 2018-04-05 2021-08-02 Sun Pharmaceutical Ind Ltd Analogos novedosos de glp-1
CN113024660B (zh) * 2018-04-19 2023-07-14 杭州先为达生物科技有限公司 酰化的glp-1衍生物
CN116925237A (zh) 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
FI4097099T3 (fi) 2020-02-07 2024-07-30 Gasherbrum Bio Inc Heterosyklisiä glp-1-agonisteja
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
CN113292646B (zh) * 2020-05-29 2022-05-13 东莞云璟生物技术有限公司 Glp-1/胰高血糖素双重激动剂融合蛋白
CR20230066A (es) 2020-08-06 2023-05-29 Gasherbrum Bio Inc Agonistas del glp-1 heterocíclicos
JP2023545684A (ja) 2020-09-30 2023-10-31 ベイジン キューエル バイオファーマシューティカル カンパニー,リミテッド ポリペプチドコンジュゲートおよび使用の方法
CN114621339B (zh) * 2021-12-28 2022-09-23 北京惠之衡生物科技有限公司 一种长效glp-1衍生物
EP4490155A1 (en) 2022-03-09 2025-01-15 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN114621340B (zh) * 2022-03-11 2022-09-23 北京惠之衡生物科技有限公司 一种酰化的长效glp-1衍生物
EP4496797A1 (en) 2022-03-21 2025-01-29 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
CA3252113A1 (en) 2022-03-30 2023-10-05 Beijing Ql Biopharmaceutical Co Ltd Liquid pharmaceutical compositions of polypeptide conjugates and their methods of use
CN114958883B (zh) * 2022-04-12 2023-01-31 北京惠之衡生物科技有限公司 一种表达glp-1类似物的重组工程菌及其构建方法
EP4508047A1 (en) 2022-04-14 2025-02-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024112617A2 (en) * 2022-11-21 2024-05-30 Eli Lilly And Company Process for preparing a gip/glp1 dual agonist
WO2024158668A1 (en) * 2023-01-23 2024-08-02 CrossChem Limited Compounds for use in keratin treatment

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233068T2 (de) 1991-02-27 2004-01-22 Micromet Ag Serin-reiche peptidlinker
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
JPH08504209A (ja) * 1992-12-04 1996-05-07 アボツト・ラボラトリーズ 6位修飾デカペプチドlhrh拮抗薬
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5663907A (en) * 1996-04-25 1997-09-02 Bright Microelectronics, Inc. Switch driver circuit for providing small sector sizes for negative gate erase flash EEPROMS using a standard twin-well CMOS process
ES2283025T3 (es) * 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
ATE466027T1 (de) * 1998-02-27 2010-05-15 Novo Nordisk As Abkömmlinge von glp-1 analogen
EP1950224A3 (en) 1998-03-09 2008-12-17 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
DK1355942T3 (da) 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
CN101665538A (zh) * 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
JP2008537873A (ja) 2004-03-31 2008-10-02 セントカー・インコーポレーテツド ヒトglp−1ミメティボディ、組成物、方法および用途
JP4933455B2 (ja) 2005-02-02 2012-05-16 ノヴォ ノルディスク アー/エス 新規のインスリン誘導体
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP2514406A1 (en) 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
ES2550363T3 (es) 2007-09-05 2015-11-06 Novo Nordisk A/S Derivados truncados de GLP-1 y su uso terapéutico
WO2009030738A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー/エス Glp−1アナログ及び誘導体
US9708383B2 (en) 2010-11-09 2017-07-18 Novo Nordisk A/S Double-acylated GLP-1 derivatives
WO2013167454A1 (en) 2012-05-08 2013-11-14 Novo Nordisk A/S Double-acylated glp-1 derivatives
JP6366575B2 (ja) 2012-05-08 2018-08-01 ノヴォ ノルディスク アー/エス 二重アシル化されたglp−1誘導体

Similar Documents

Publication Publication Date Title
JP2014529629A5 (enExample)
JP2013543853A5 (enExample)
JP2014501712A5 (enExample)
RU2013148921A (ru) Дважды ацилированные производные glp-1
JP2015517478A5 (enExample)
JP2017514801A5 (enExample)
JP2015517477A5 (enExample)
JP2016523243A5 (enExample)
JP2010538049A5 (enExample)
JP2017105819A5 (enExample)
JP2016529253A5 (enExample)
JP2013517307A5 (enExample)
JP2014503526A5 (enExample)
JP2018506507A5 (enExample)
CN107812181B (zh) Glp-1肽组合物及其制备
JP2008533105A5 (enExample)
US11167014B2 (en) Solid glp-1 derivative compositions for oral administration
JP2005528337A5 (enExample)
CN103189389B (zh) 新的glp‑ⅰ类似物及其制备方法和用途
CN111132690A (zh) 胰高血糖素和glp-1受体的长效共激动剂
JP2007519642A5 (enExample)
JP2016526012A5 (enExample)
JP2022095872A (ja) ヒトインスリンまたはそのアナログのアシル化誘導体
EP2844269A1 (en) Transmucosal delivery of engineered polypeptides
JP2019513126A5 (enExample)